Last reviewed · How we verify

GNbAC1 — Competitive Intelligence Brief

GNbAC1 (GNbAC1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fc receptor antagonist. Area: Autoimmune diseases.

phase 2 Fc receptor antagonist Fc region of IgG1 Autoimmune diseases Biologic Live · refreshed every 30 min

Target snapshot

GNbAC1 (GNbAC1) — GeNeuro Innovation SAS. GNbAC1 is a recombinant immunoglobulin targeting the human immunoglobulin G1 (IgG1) Fc region.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GNbAC1 TARGET GNbAC1 GeNeuro Innovation SAS phase 2 Fc receptor antagonist Fc region of IgG1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fc receptor antagonist class)

  1. GeNeuro Innovation SAS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GNbAC1 — Competitive Intelligence Brief. https://druglandscape.com/ci/gnbac1. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: